查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1803084

2032 年肝纖維化治療市場預測：按治療類型、疾病狀況、通路和地區進行的全球分析

Liver Fibrosis Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Condition, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球肝纖維化治療市場預計在 2025 年達到 207.1 億美元，預計到 2032 年將達到 488.7 億美元，預測期內的複合年成長率為 13.05%。

肝纖維化的治療旨在減少或逆轉持續性肝損傷和發炎引起的疤痕組織形成。治療包括控制潛在原因，例如病毒性肝炎、飲酒或非酒精性脂肪性肝病，並透過藥物治療、生活方式改變和支持性治療相結合的方式，最大限度地減少進一步的損害。及時治療可保護肝功能，減緩病情進展，降低肝硬化的風險，最終改善整體健康狀況和預後。

根據美國國家酒精濫用和酒精成癮研究所 (2023) 的數據，到 2022 年，美國將有約 2,950 萬人遭受酒精成癮困擾，佔 12 歲及以上人口的 10.5%。

老年人口不斷增加

全球人口老化顯著推動了肝纖維化治療的需求。由於老齡化相關的免疫力減弱以及長期暴露於代謝壓力源，老年人更容易受到肝損傷。肥胖、糖尿病和心臟病等疾病通常並存，並加速肝臟功能惡化。隨著人們壽命的延長，醫療保健提供者發現老年患者需要客製化治療方法。這一趨勢正在推動醫藥創新，專注於為老年人提供更安全、更有效的抗纖維化藥物選擇。最終，人口老化正在擴大治療市場，並影響臨床開發的方向。

核准的抗纖維化藥物供應有限

大多數現有療法著重於控制潛在病因，例如病毒性肝炎和脂肪肝，而非逆轉纖維化疾病。複雜的監管和漫長的研發週期阻礙了新治療方法的推廣。許多有前景的化合物仍處於早期研究階段，導致臨床醫生難以找到合適的治療方案。這種藥物短缺影響了患者護理，並限制了市場擴張，尤其是在高負擔地區。在更多抗纖維化藥物核准之前，治療方案可能仍然有限。

遠端醫療和數位健康平台的擴展

數位醫療和遠端醫療的興起為肝纖維化的管理開闢了新的途徑。虛擬會診使患者能夠聯繫肝病專家並獲得及時治療，尤其是在偏遠和服務不足的地區。穿戴式裝置和行動應用程式可以監測肝功能指標並支持藥物依從性。這些技術還能實現個人化治療方案，改善病患教育，並促進更好的健康結果。隨著數位醫療成為主流，肝纖維化的治療正變得更加積極且易於獲得。預計這一轉變將促進創新治療方法的廣泛應用，並加強疾病管理。

來自替代療法的競爭

替代療法正日益挑戰傳統肝纖維化治療的優勢。生活型態改變、飲食介入和代謝控制等預防策略正逐漸成為第一線治療手段。再生技術和細胞療法也提供了繞過傳統藥物治療的全新解決方案。這些日益廣泛的治療選擇或許可以減少對藥物介入的依賴。此外，如果非侵入性方法被證明有效，臨床醫生在採用新藥時可能會更加謹慎。

COVID-19的影響：

COVID-19疫情對肝纖維化治療市場造成了顯著影響，導致診斷、常規檢查和不必要的醫療程序延誤。治療計劃經常被推遲，這可能導致部分患者的病情惡化。供應鏈中斷阻礙了藥品和診斷工具的供應。 COVID-19對肝功能的潛在影響凸顯了早期發現和有效治療的重要性。

過氧化物酶體增殖劑部分預計將在預測期內成為最大的

由於高通量篩檢和分子建模等藥物發現技術的進步，過氧化物酶體增殖物領域預計將在預測期內佔據最大的市場佔有率。諸如雙PPAR促效劑和泛PPAR促效劑的開發等新興趨勢提供了更廣泛的治療益處。關鍵進展包括令人鼓舞的臨床試驗結果以及製藥公司之間為加速創新而建立的策略聯盟。非酒精性脂肪性肝炎(NASH)及其相關代謝紊亂的盛行率不斷上升，使得基於PPAR的療法成為肝纖維化管理的關鍵領域，從而進一步推動需求。

預計醫院藥房部門在預測期內將出現最高的複合年成長率。

隨著自動配藥和電子處方系統等配藥技術的進步，醫院藥局預計將在預測期內實現最高成長率。新興趨勢包括整合遠距配藥服務以及針對肝病患者的個人化醫療方案。此外，醫院與製藥公司合作進行臨床試驗以及加速藥物可及性計畫等發展也取得了進展。肝臟相關疾病住院率的上升以及先進治療方法的日益普及，進一步加強了醫院藥房在醫療服務中的作用。

佔比最大的地區：

由於與肝炎、非酒精性脂肪性肝炎 (NASH) 和酒精性肝損傷相關的病例增加，預計亞太地區將在預測期內佔據最大的市場佔有率。非侵入性成像和 RNA 療法的技術創新正在增強早期診斷和標靶治療。市場對數位健康和​​個人化治療方法的採用正在成長。值得注意的發展包括印度、日本和中國候選藥物和測試活動的擴展。人口老化、健康意識的增強以及政府投資的增加正在推動技術進步和區域市場的成長。

複合年成長率最高的地區：

在預測期內，北美預計將見證最高的複合年成長率，這得益於北美強大的醫療體系和研究資金的支持，以及NASH、NAFLD和肝炎的盛行率不斷上升。人工智慧主導的診斷、非侵入性技術和RNA療法的突破正在提高準確性和早期療育。遠端醫療和個人化治療等趨勢也在推動市場發展。最近的發展包括新的PPAR標靶藥物、聯合治療和不斷擴大的臨床試驗網路。不斷提高的健康素養、有利的法規和活躍的藥物研發線正在推動全部區域市場的持續擴張。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球肝纖維化治療市場（依治療類型）

  • 血管緊張素轉換酶抑制劑
  • 抗病毒藥物
  • 細胞療法
  • 過氧化物酶體增殖物
  • FXR促效劑
  • 標靶治療
  • 肝病藥物
  • 其他治療類型

6. 全球肝纖維化治療市場（依疾病類型）

  • 非酒精性脂肪性肝炎（NASH）
  • 慢性肝病
  • C型肝炎
  • 酒精性肝臟疾病
  • 遺傳性疾病
  • 自體免疫肝炎

7. 全球肝纖維化治療市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

8. 全球肝纖維化治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章：企業概況

  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Akero Therapeutics
  • Hepion Pharmaceuticals
  • Alentis Therapeutics
  • Inventiva Pharma
  • Alnylam Pharmaceuticals
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Novartis AG
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi AG
  • Vertex Pharmaceuticals Incorporated
  • Galectin Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Gilead Sciences, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
Product Code: SMRC30609

According to Stratistics MRC, the Global Liver Fibrosis Treatment Market is accounted for $20.71 billion in 2025 and is expected to reach $48.87 billion by 2032 growing at a CAGR of 13.05% during the forecast period. Treatment for liver fibrosis targets the reduction or reversal of scar tissue formation resulting from ongoing liver damage or inflammation. It involves managing the root cause like viral hepatitis, alcohol consumption, or nonalcoholic fatty liver alongside medications, lifestyle modifications, and supportive care to minimize further harm. Timely treatment helps preserve liver function, slows disease progression, and lowers the risk of developing cirrhosis, ultimately improving overall health and prognosis.

According to the National Institute on Alcohol Abuse and Alcoholism 2023, in 2022, about 29.5 million individuals in the United States with alcohol dependence, or 10.5% of individuals aged between 12 years and above.

Market Dynamics:

Driver:

Growing geriatric population

The increasing number of elderly individuals worldwide is significantly boosting demand for liver fibrosis treatments. Older adults are more prone to liver disorders due to age-related immune decline and long-term exposure to metabolic stressors. Conditions like obesity, diabetes, and heart disease often coexist, accelerating liver deterioration. As longevity rises, healthcare providers are seeing a growing need for therapies tailored to older patients. This trend is encouraging pharmaceutical innovation focused on safer and more effective anti-fibrotic options for seniors. Eventually, the aging demographic is expanding the treatment market and influencing the direction of clinical development.

Restraint:

Limited availability of approved anti-fibrotic drugs

Most available therapies concentrate on managing underlying causes such as viral hepatitis or fatty liver disease, rather than reversing fibrotic damage. Regulatory complexities and extended development timelines have slowed the introduction of new treatments. Many promising compounds are still in early research phases, leaving clinicians with few targeted solutions. This shortage affects patient care and restricts market expansion, particularly in high-burden regions. Until more anti-fibrotic agents receive approval, treatment options will remain constrained.

Opportunity:

Expansion of telemedicine and digital health platforms

The rise of digital health and telemedicine is opening new avenues for managing liver fibrosis. Virtual consultations allow patients to access liver specialists and receive timely care, especially in remote or underserved areas. Wearables and mobile apps can monitor liver function indicators and support medication adherence. These technologies also enable customized treatment plans and improve patient education, fostering better health outcomes. As digital healthcare becomes mainstream, liver fibrosis care is becoming more proactive and accessible. This shift is expected to drive broader adoption of innovative therapies and enhance disease management.

Threat:

Competition from alternative therapies

Alternative therapies are increasingly challenging the dominance of traditional liver fibrosis treatments. Preventive strategies like lifestyle changes, dietary interventions, and metabolic control are gaining traction as first-line approaches. Regenerative techniques and cell-based therapies also offer novel solutions that may bypass conventional drug treatments. This expanding range of options could reduce reliance on pharmacological interventions. Additionally, clinicians may be cautious about adopting new drugs if non-invasive methods prove effective.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the Liver Fibrosis Treatment Market, causing delays in diagnostics, routine check-ups, and non-essential medical procedures. Treatment schedules were often postponed, resulting in possible disease advancement for some patients. Disruptions in supply chains hindered the availability of medicines and diagnostic tools. On the positive side, the crisis spurred the adoption of telemedicine and heightened awareness of liver health, as COVID-19's potential impact on liver function emphasized the importance of early detection and effective care.

The peroxisome proliferator segment is expected to be the largest during the forecast period

The peroxisome proliferator segment is expected to account for the largest market share during the forecast period, driven by advancements in drug discovery technologies, including high-throughput screening and molecular modelling. Emerging trends such as the development of dual and pan-PPAR agonists offer broader therapeutic benefits. Key developments include promising clinical trial results and strategic collaborations between pharmaceutical companies to accelerate innovation. Increasing prevalence of nonalcoholic steatohepatitis (NASH) and related metabolic disorders further fuels demand, positioning PPAR-based treatments as a vital segment in liver fibrosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospital pharmacies segment is predicted to witness the highest growth rate, driven by advancements in pharmaceutical dispensing technologies, such as automated drug distribution and electronic prescription systems, enhancing efficiency and accuracy. Emerging trends include integration of telepharmacy services and personalized medicine approaches for liver disease patients. Developments like hospital collaborations with pharmaceutical companies for clinical trials and early drug access programs. Rising hospitalization rates for liver-related conditions and increasing availability of advanced therapies further strengthen the role of hospital pharmacies in treatment delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to escalating cases linked to hepatitis, NASH, and alcohol-induced liver damage. Innovations in non-invasive imaging and RNA therapeutics are enhancing early diagnosis and targeted care. The market is seeing growth in digital health adoption and personalized treatment approaches. Notable progress includes new drug candidates and expanded trial activity in India, Japan, and China. Aging populations, rising health awareness, and increased government investment are fueling technological advancement and regional market growth.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to growing prevalence of NASH, NAFLD, and hepatitis, supported by robust healthcare systems and research funding. Breakthroughs in AI-driven diagnostics, non-invasive technologies, and RNA therapeutics are improving accuracy and early intervention. Trends like telemedicine and tailored treatment approaches are gaining traction. Recent progress includes new PPAR-targeting drugs, multi-modal regimens, and expanded trial networks. Rising health literacy, favourable regulations, and active pharmaceutical pipelines are driving sustained market expansion across the region.

Key players in the market

Some of the key players in Liver Fibrosis Treatment Market include Abbott Laboratories, Bristol-Myers Squibb Company, Akero Therapeutics, Hepion Pharmaceuticals, Alentis Therapeutics, Inventiva Pharma, Alnylam Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc., Novartis AG, Boehringer Ingelheim, Merck & Co., Inc., Pfizer Inc., Sanofi AG, Vertex Pharmaceuticals Incorporated, Galectin Therapeutics, Inc., Takeda Pharmaceutical Company, Gilead Sciences, Inc., Madrigal Pharmaceuticals, Inc., and GlaxoSmithKline PLC.

Key Developments:

In July 2025, Johnson & Johnson MedTech announced a strategic co-promotion agreement with Pacira BioSciences, Inc., the industry leader in the delivery of innovative, non-opioid pain therapies. The agreement expands the Company's Early Intervention portfolio with ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) an extended-release injectable for treatment of pain related to osteoarthritis (OA) of the knee.

In June 2025, Bristol Myers Squibb and BioNTech SE announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history - a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Treatment Types Covered:

  • ACE Inhibitors
  • Antiviral Drugs
  • Cell Therapy
  • Peroxisome Proliferator
  • FXR Agonists
  • Targeted Therapy
  • Hepatotropic Drugs
  • Other Treatment Types

Conditions Covered:

  • Nonalcoholic Steatohepatitis (NASH)
  • Chronic Liver Diseases
  • Hepatitis C
  • Alcoholic Liver Disease
  • Genetic Disorders
  • Autoimmune Hepatitis

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liver Fibrosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 ACE Inhibitors
  • 5.3 Antiviral Drugs
  • 5.4 Cell Therapy
  • 5.5 Peroxisome Proliferator
  • 5.6 FXR Agonists
  • 5.7 Targeted Therapy
  • 5.8 Hepatotropic Drugs
  • 5.9 Other Treatment Types

6 Global Liver Fibrosis Treatment Market, By Condition

  • 6.1 Introduction
  • 6.2 Nonalcoholic Steatohepatitis (NASH)
  • 6.3 Chronic Liver Diseases
  • 6.4 Hepatitis C
  • 6.5 Alcoholic Liver Disease
  • 6.6 Genetic Disorders
  • 6.7 Autoimmune Hepatitis

7 Global Liver Fibrosis Treatment Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Online Pharmacies
  • 7.4 Retail Pharmacies

8 Global Liver Fibrosis Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Bristol-Myers Squibb Company
  • 10.3 Akero Therapeutics
  • 10.4 Hepion Pharmaceuticals
  • 10.5 Alentis Therapeutics
  • 10.6 Inventiva Pharma
  • 10.7 Alnylam Pharmaceuticals
  • 10.8 Johnson & Johnson
  • 10.9 Astellas Pharma Inc.
  • 10.10 Novartis AG
  • 10.11 Boehringer Ingelheim
  • 10.12 Merck & Co., Inc.
  • 10.13 Pfizer Inc.
  • 10.14 Sanofi AG
  • 10.15 Vertex Pharmaceuticals Incorporated
  • 10.16 Galectin Therapeutics, Inc.
  • 10.17 Takeda Pharmaceutical Company
  • 10.18 Gilead Sciences, Inc.
  • 10.19 Madrigal Pharmaceuticals, Inc.
  • 10.20 GlaxoSmithKline PLC

List of Tables

  • Table 1 Global Liver Fibrosis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 4 Global Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 5 Global Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 6 Global Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 7 Global Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 8 Global Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 9 Global Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 10 Global Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 11 Global Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 12 Global Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 13 Global Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 14 Global Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 15 Global Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 16 Global Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 17 Global Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 18 Global Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 19 Global Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 20 Global Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 21 Global Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 22 North America Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 23 North America Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 24 North America Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 25 North America Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 26 North America Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 27 North America Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 28 North America Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 29 North America Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 30 North America Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 31 North America Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 32 North America Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 33 North America Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 34 North America Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 35 North America Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 36 North America Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 37 North America Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 38 North America Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 39 North America Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 40 North America Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 41 North America Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 42 North America Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 43 Europe Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 44 Europe Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 45 Europe Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 46 Europe Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 47 Europe Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 48 Europe Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 49 Europe Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 50 Europe Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 51 Europe Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 52 Europe Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 53 Europe Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 54 Europe Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 55 Europe Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 56 Europe Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 57 Europe Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 58 Europe Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 59 Europe Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 60 Europe Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 61 Europe Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 62 Europe Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 63 Europe Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 64 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 65 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 66 Asia Pacific Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 67 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 68 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 69 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 70 Asia Pacific Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 71 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 72 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 73 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 74 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 75 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 76 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 77 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 78 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 79 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 80 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 81 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 82 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 83 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 84 Asia Pacific Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 85 South America Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 86 South America Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 87 South America Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 88 South America Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 89 South America Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 90 South America Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 91 South America Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 92 South America Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 93 South America Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 94 South America Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 95 South America Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 96 South America Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 97 South America Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 98 South America Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 99 South America Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 100 South America Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 101 South America Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 102 South America Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 103 South America Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 104 South America Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 105 South America Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 106 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 107 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 108 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By ACE Inhibitors (2024-2032) ($MN)
  • Table 109 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Antiviral Drugs (2024-2032) ($MN)
  • Table 110 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 111 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Peroxisome Proliferator (2024-2032) ($MN)
  • Table 112 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By FXR Agonists (2024-2032) ($MN)
  • Table 113 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 114 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hepatotropic Drugs (2024-2032) ($MN)
  • Table 115 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 116 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Condition (2024-2032) ($MN)
  • Table 117 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Nonalcoholic Steatohepatitis (NASH) (2024-2032) ($MN)
  • Table 118 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Chronic Liver Diseases (2024-2032) ($MN)
  • Table 119 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hepatitis C (2024-2032) ($MN)
  • Table 120 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Alcoholic Liver Disease (2024-2032) ($MN)
  • Table 121 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 122 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Autoimmune Hepatitis (2024-2032) ($MN)
  • Table 123 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 124 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 125 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 126 Middle East & Africa Liver Fibrosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)